Skip to main content
logo
International Flavors & Fragrances Inc. (BIT:1IFF)
Italy flag Italy · Delayed Price · Currency is EUR
68.56
+3.16 (4.83%)
At close: Mar 5, 2026

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Taste Revenue
2.48B2.43B
Taste Revenue Growth
2.18%-
Food Ingredients Revenue
3.28B3.37B
Food Ingredients Revenue Growth
-2.58%-
Health & Biosciences Revenue
2.28B2.20B
Health & Biosciences Revenue Growth
3.63%5.86%
Scent Revenue
2.48B2.44B
Scent Revenue Growth
1.64%1.92%
Pharma Solutions Revenue
369.00M1.05B
Pharma Solutions Revenue Growth
-64.82%11.00%
Revenue (Other)
--
Revenue (Total)
10.89B11.48B
Revenue (Total) Growth
-5.17%0.04%

Adjusted EBITDA

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Taste Adjusted Operating EBITDA
478.00M460.00M
Taste Adjusted Operating EBITDA Growth
3.91%-
Food Ingredients Adjusted Operating EBITDA
423.00M408.00M
Food Ingredients Adjusted Operating EBITDA Growth
3.68%-
Health & Biosciences Adjusted Operating EBITDA
594.00M577.00M
Health & Biosciences Adjusted Operating EBITDA Growth
2.95%-1.87%
Scent Adjusted Operating EBITDA
515.00M545.00M
Scent Adjusted Operating EBITDA Growth
-5.50%18.22%
Pharma Solutions Adjusted Operating EBITDA
76.00M215.00M
Pharma Solutions Adjusted Operating EBITDA Growth
-64.65%8.04%
Operating Income (Total)
-382.00M766.00M

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Nourish Capital Expenditures
322.00M235.00M
Nourish Capital Expenditures Growth
37.02%-6.75%
Health & Biosciences Capital Expenditures
145.00M73.00M
Health & Biosciences Capital Expenditures Growth
98.63%-14.12%
Scent Capital Expenditures
89.00M70.00M
Scent Capital Expenditures Growth
27.14%12.90%
Pharma Solutions Capital Expenditures
38.00M85.00M
Pharma Solutions Capital Expenditures Growth
-55.29%-18.27%
Updated Dec 31, 2025. Data Source: Fiscal.ai.